Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.
Management of patients with pancreatic cancer is a multidisciplinary approach that presents enormous challenges to the clinician. Overall 5-year survival for all patients remains <3%. Symptoms of early pancreas cancer are nonspecific. As such, only a fraction of patients are candidates for surgery. While surgical resection provides the only curative option, most patients will develop tumor recurrence and die of their disease. To date, the clinical benefits of chemotherapy and radiation therapy have been important but have led to modest improvements. Tumor vaccines have the potential to specifically target the needle of pancreas cancer cells amidst the haystack of normal tissue. The discovery of pancreas tumor-specific antigens and the subsequent ability to harness this technology has become an area of intense interest for tumor immunologists and clinicians alike. Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer.
The Sidney Kimmel Cancer Center, the Skip Viragh Clinical Pancreatic Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. Laherda@jhmi.edu
Dan
D
Laheru
Barbara
B
Biedrzycki
Elizabeth M
EM
Jaffee
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D016207:Cytokines / Q000235:genetics / Q000276:immunology*; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D041681:NIH 3T3 Cells; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic
D019496:Cancer Vaccines; D016207:Cytokines